The significance of mitochondrial toxicity testing in drug development.
about
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryModelling age-related metabolic disorders in the mouseUridine prevents fenofibrate-induced fatty liverNovel gene function revealed by mouse mutagenesis screens for models of age-related disease.Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansMitochondria as a target in treatmentSerendipity and the discovery of novel compounds that restore mitochondrial plasticityAnalysis of the influence of cell heterogeneity on nanoparticle dose responseBioenergetic profiling of zebrafish embryonic developmentEvaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytesA New Structure-Activity Relationship (SAR) Model for Predicting Drug-Induced Liver Injury, Based on Statistical and Expert-Based Structural AlertsMicrochannel acoustophoresis does not impact survival or function of microglia, leukocytes or tumor cells.Bafilomycin A1 activates respiration of neuronal cells via uncoupling associated with flickering depolarization of mitochondriaProposal of an in silico profiler for categorisation of repeat dose toxicity data of hair dyes.Acute Toxicity Prediction in Multiple Species by Leveraging Mechanistic ToxCast Mitochondrial Inhibition Data and Simulation of Oral Bioavailability.ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspectiveDesign considerations for an integrated microphysiological muscle tissue for drug and tissue toxicity testingA high-throughput respirometric assay for mitochondrial biogenesis and toxicity.Potential therapeutic benefits of strategies directed to mitochondria.Systematic study of mitochondrial toxicity of environmental chemicals using quantitative high throughput screening.The anti-mitochondrial antifungal assay for the discovery and development of new drugs.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Lung tissue bioenergetics and caspase activity in rodents.Enhanced human tissue microdialysis using hydroxypropyl-ß-cyclodextrin as molecular carrier.High-throughput respirometric assay identifies predictive toxicophore of mitochondrial injury.Mechanisms of cell death pathway activation following drug-induced inhibition of mitochondrial complex I.β-Adrenergic receptor blockade blunts postexercise skeletal muscle mitochondrial protein synthesis rates in humansHigh-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects.The acute extracellular flux (XF) assay to assess compound effects on mitochondrial function.Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findingsPrediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria.Drug-induced mitochondrial dysfunction and cardiotoxicity.Bafilomycin A1 activates HIF-dependent signalling in human colon cancer cells via mitochondrial uncouplingYeast sensors for novel drugs: chloroquine and others revealedAssessing neuronal bioenergetic status.Mitochondria as a target of environmental toxicants.Cognitive Impairment Associated with Parkinson's Disease: Role of Mitochondria.Statin myopathy as a metabolic muscle disease.Integrative toxicoproteomics implicates impaired mitochondrial glutathione import as an off-target effect of troglitazoneManagement of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm.
P2860
Q26749054-4658C701-D58E-41A7-AB01-B74EB5B531D8Q27024434-DE3B3E0C-1904-49C8-BD20-1DD50806E4D9Q27325516-37E9FB1E-20F9-433C-9EAA-8E1256D711BBQ27333508-0F3C676A-564B-4DAF-99FA-65C2CCDB50B3Q28075991-449F402E-E6A9-473A-87C7-E55BAFB64334Q28382780-90DE5171-8924-4BB6-9D58-70C558E356E3Q28384256-6A033F8D-7C26-4F1D-B6F4-4EEB0D373E04Q28396936-1ACB7BEB-620A-4211-98A7-F8DB2A4CF983Q28477289-77F50343-3B85-4B2E-BA38-CEBF6F637579Q28542837-A54FA82A-C290-4932-85C0-60D24FFA8E58Q28820944-0CF53C80-3585-4F20-B9AB-68787AC8400EQ30454243-F6454B0C-E4F8-4E47-8FCF-0E57EBC3DB0DQ30498146-AE001DC4-2CC9-44E7-B668-B51E62DC99A0Q30828343-1739C85F-FAE4-4DF0-826B-B61B84269DDEQ30978377-EE099BFB-CC09-4D07-BFEA-54545A0BD394Q33469822-51B67D63-9421-4CBB-B02B-AD2FB22A6B4AQ33643355-3AFAC855-D957-481A-843D-116ECC59D7D3Q33976815-7CF41E8D-AB02-474A-8608-B0AFC3D93A3BQ34117168-ED072A1F-EDEC-4508-BBB3-36FF215FBB07Q34130812-38DEA5A6-3632-48C8-8E90-04B89E69D7E3Q34278041-4FA69181-DCC3-4717-B167-885516394542Q34409132-2A254B62-5CD4-4DCD-B752-B0326F1EF048Q34545964-A54BB498-CDC0-4D66-9054-A5403CE511CDQ34663873-EA101603-29F7-4027-8C47-1C17EA79ED8AQ34786843-E660D245-FD0E-4BEE-9265-595F6DA3325FQ35045143-BE6A6BE1-28B7-4CF1-BC19-CC8A76D5FAC0Q35160064-1767BCE4-296E-472A-BEC4-0A5A45F9965FQ35208534-B8AB7482-3B73-4BF8-892B-F0C382D38835Q35405000-E24BCDAA-D87E-48ED-A6A7-8E9643DEFF5EQ35603973-F935D8B0-21F1-426D-AFD6-229DCD377418Q36247086-A76A70D4-885A-4E2A-BF92-A2A3351CB79DQ36339445-ADCCF479-3258-4EFE-95BE-75EB643B2005Q36397685-87CA3BFD-D0E9-4A99-A10D-47744F3C5F92Q36534476-E9ABF1C5-5A2C-43DE-A533-13F35AFCE35DQ36919468-43456DBB-15FB-4460-8F5F-C648622A3AC1Q36956066-2D042645-72D0-40E1-9018-D61C634DCC7EQ37168743-819B3EC8-0CD0-4335-A290-F12418F78F3EQ37230388-AAD3109E-2F12-409F-BA57-7F4654D05464Q37247744-470515D7-942D-48A6-9432-56F1B11303E0Q37309094-2A3E545D-8636-49A0-8B7C-29A91817AA57
P2860
The significance of mitochondrial toxicity testing in drug development.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The significance of mitochondrial toxicity testing in drug development.
@en
type
label
The significance of mitochondrial toxicity testing in drug development.
@en
prefLabel
The significance of mitochondrial toxicity testing in drug development.
@en
P1433
P1476
The significance of mitochondrial toxicity testing in drug development.
@en
P2093
James A Dykens
Yvonne Will
P304
P356
10.1016/J.DRUDIS.2007.07.013
P577
2007-08-22T00:00:00Z